

AD _____

Award Number: W81XWH-04-1-0372

TITLE: CTL-Tumor Cell Interaction: The Generation of Molecular Probes Capable of Monitoring the HLA-A*0201-HER-2/neu Peptide Complex

PRINCIPAL INVESTIGATOR: Eric C. Ko

CONTRACTING ORGANIZATION: Health Research, Incorporated
Roswell Park Cancer Institute
Buffalo, NY 14263

REPORT DATE: March 2007

TYPE OF REPORT: Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE 01-03-2007		2. REPORT TYPE Annual Summary		3. DATES COVERED 27 Feb 2004 – 26 Feb 2007	
4. TITLE AND SUBTITLE CTL-Tumor Cell Interaction: The Generation of Molecular Probes Capable of Monitoring the HLA-A*0201-HER-2/neu Peptide Complex				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-04-1-0372	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Eric C. Ko Email: "Eric Ko" eric.c.ko@gmail.com				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Health Research, Incorporated Roswell Park Cancer Institute Buffalo, NY 14263				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT The overall goal of this project is to probe the CTL – tumor cell interaction by generating scFv probes that are able to recognize the HLA-A*0201-HER-2/neu369-377 peptide complex. In the second 12-month funding period (Feb 2005 – Feb 2006), scFv 2.3.5-58-53 was isolated following site-directed mutagenesis in the VL CDR3 and VL CDR1 of HLA-A*0201:HER-2/neu369-377 complex-specific scFv 2.3.5. In the 12-month period covered by this report (Feb 2006 – Feb 2007), I aimed to further improve the recognition of HLA-A*0201-HER-2/neu369-377 complexes by scFv 2.3.5-58-53. To this end, an scFv-Fc construct was utilized in an attempt to improve the avidity of the scFv for HLA-A*0201:HER-2/neu369-377 complexes expressed on tumor cells. Although scFv 2.3.5-58-53-Fc demonstrated modestly enhanced reactivity with HER-2/neu369-377 peptide-pulsed T2 cells when compared with scFv 2.3.5-58-53, it did not exhibit enhanced reactivity with HLA-A2+HER-2/neu+ tumor cells PCA-30 and MDA-MB-231. We are actively investigating several possibilities that may account for this discrepancy.					
15. SUBJECT TERMS Tumor immunology; Immunotherapy; HLA class I antigen; Antigen presentation					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U			USAMRMC
			UU	10	19b. TELEPHONE NUMBER (include area code)

Table of Contents

Introduction.....	4
Body.....	5
Key Research Accomplishments.....	7
Reportable Outcomes.....	8
Conclusions.....	9
References.....	10
Appendices.....	N/A

INTRODUCTION

This document is the final report of DOD Predoctoral Fellowship Award BC030039, entitled “CTL – Tumor Cell Interaction: The generation of molecular probes capable of monitoring the HLA-A*0201-HER-2/neu peptide complex”. It is intended to communicate the research progress related to this award mechanism in the 12-month period spanning from February 2006 through February 2007.

A major limitation to the utilization of the HLA-A*0201:HER-2/neu₃₆₉₋₃₇₇ complex-specific scFv 2.3.5, which was isolated during the first 12-month funding period, was its low affinity to the native complexes on breast carcinoma cells. During the second 12-month funding period, we utilized molecular biology approaches to introduce site-specific amino acid changes in the complementarity-determining regions (CDRs) of scFv 2.3.5, with the aim of isolating a clone with higher affinity for the HLA-A*0201:HER-2/neu₃₆₉₋₃₇₇ complex. scFv 2.3.5-58-53 exhibited markedly higher affinity for the HLA-A*0201:HER-2/neu₃₆₉₋₃₇₇ complex than the parental scFv 2.3.5.

In the previous 12-month funding period, we sought to further enhance the affinity of the scFv 2.3.5-58-53 to detect HLA-A*0201:HER-2/neu₃₆₉₋₃₇₇ complexes, whether these complexes were those found on peptide-pulsed T2 cells or native complexes located on the surface of breast carcinoma cells. To accomplish this goal, we utilized an available DNA construct, which inserted human Fc at the C-terminal end of the scFv in order to increase its avidity. Although we noted a modest improvement in the ability of scFv 2.3.5-58-53-Fc to detect HER-2/neu₃₆₉₋₃₇₇ peptide-pulsed T2 cells, compared with the parental scFv 2.3.5-58-53, no improvement was noted in its ability to react with PCI-30 or MDA-MB-231 cells, each of which is HLA-A2⁺HER-2/neu⁺ and expected to express some native HLA-A2:HER-2/neu₃₆₉₋₃₇₇ complexes on their surface. It is not clear if these negative findings are due to the concentration of scFv-Fc reagent utilized, and/or the low density of native HLA-A2:HER-2/neu₃₆₉₋₃₇₇ complexes on these cells.

RESULTS

I. Reactivity of purified scFv-Fc with peptide-pulsed T2 cells

During the course of the second 12-month funding period for this fellowship, we utilized molecular biology approaches to increase the affinity of scFv 2.3.5, which is specific for the HLA-A*0201:HER-2/neu₃₆₉₋₃₇₇ complex. We performed three rounds of mutagenesis: (i) Alanine-scanning mutagenesis of V_L CDR3; (ii) Alanine-scanning mutagenesis of V_L CDR1; and (iii) Site-directed random mutagenesis of V_L CDR1. We obtained a scFv clone, named 2.3.5-58-53, which has been mutagenized in both its V_L CDR3 (M89T, Q90A, L94V) and V_L CDR1 (L27cA, H27dA, S27eP) regions. scFv 2.3.5-58-53 exhibited markedly higher affinity for the HLA-A*0201:HER-2/neu₃₆₉₋₃₇₇ complex than the parental scFv 2.3.5.

In the most recent 12-month funding period, we sought to further improve the affinity of scFv 2.3.5-58-53, in order to increase its sensitivity in detecting low to moderate amounts of native HLA-A*0201:HER-2/neu₃₆₉₋₃₇₇ complexes found on breast carcinoma cells. To this end, we collaborated with investigators at EMD-Lexigen (Billerica, MA), who had a DNA construct that allowed insertion of human Fc at the C-terminal end of our protein of interest. We expected this modification to improve the avidity of scFv 2.3.5-58-53, thereby enhancing its ability to detect HLA-A*0201:HER-2/neu₃₆₉₋₃₇₇ complexes. We noted that there was a modest improvement in the reactivity of scFv 2.3.5-58-53-Fc with HER-2/neu₃₆₉₋₃₇₇ peptide-pulsed T2 cells (**Fig. 1**). Significantly, this modification did not affect the background reactivity of the same scFv-Fc reagent with irrelevant MART1₂₆₋₃₅ peptide-pulsed T2 cells.





Fig. 1. Reactivity of purified scFv-Fc with peptide-pulsed T2 cells. scFv 2.3.5-58-53-Fc (25 µg/ml) was compared to parental scFv 2.3.5-58-53 for its reactivity to T2 cells pulsed with HER-2/neu₃₆₉₋₃₇₇ peptide (50 µg/ml) (top panel). The HLA-A*0201:MART1₂₆₋₃₅ complex-specific scFv 8.3-21, scFv 8.3-21-Fc, and the HLA-A2,A28-specific mAb KS-1 were utilized as negative and positive controls, respectively. T2 cells pulsed with MART1₂₆₋₃₅ peptide (50 µg/ml) (bottom panel) were utilized as a specificity control.

II. Reactivity of scFv 2.3.5-58-53-Fc with malignant tumor cells

We also tested the reactivity of scFv 2.3.5-58-53-Fc with a panel of malignant tumor cells, including PCI-30 (HLA-A2⁺HER-2⁺), MDA-MB-157 (HLA-A2⁻HER-2⁺), MDA-MB-231 (HLA-A2⁺HER-2⁺), SK-OV-3 (HLA-A2⁻HER-2⁺), and PCI-13 (HLA-A2⁺HER-2⁻) (**Fig. 2**). Very little to no reactivity was noted for all of these cells, including HLA-A2⁺HER-2⁺ PCI-30 and MDA-MB-231 cells. It is not clear if these negative findings are due to the concentration of scFv-Fc reagent utilized, and/or the low density of native HLA-A2:HER-2/neu₃₆₉₋₃₇₇ complexes on these cells.



KEY RESEARCH ACCOMPLISHMENTS

- Synthesized and purified scFv 2.3.5-58-53-Fc protein, which is based on the HLA-A*0201:HER-2/neu₃₆₉₋₃₇₇ complex-specific scFv 2.3.5-58-53.
- Demonstrated that scFv 2.3.5-58-53-Fc has modestly enhanced reactivity with HER-2/neu₃₆₉₋₃₇₇ peptide-pulsed T2 cells, compared with scFv 2.3.5-58-53.
- Demonstrated that scFv 2.3.5-58-53-Fc has very low reactivity with HLA-A2⁺HER-2/neu⁺ tumor cells PCI-30 and MDA-MB-231, which is consistent with findings utilizing scFv 2.3.5-58-53. It remains unclear whether the limited reactivity with tumor cells, despite positive findings with peptide-pulsed T2 cells, reflects the concentration of scFv-Fc reagent utilized, and/or the low density of native HLA-A2:HER-2/neu₃₆₉₋₃₇₇ complexes on the tumor cells.

REPORTABLE OUTCOMES

1. Ogino T, Miyokawa N, Ko E, Ferrone S. HLA class I antigen abnormalities in cancer: Molecular mechanism, clinical significance and negative impact for T cell-based immunotherapy. *Manuscript in preparation*.

CONCLUSIONS

In the course of the last 12 months, I have carried out a series of experiments to further enhance the reactivity of the HLA-A*0201:HER-2/neu₃₆₉₋₃₇₇ complex-specific scFv 2.3.5, and its mutagenized derivative scFv 2.3.5-58-53. In collaboration with EMD-Lexigen, an scFv-Fc reagent was generated, based on scFv 2.3.5-58-53 and hence termed scFv 2.3.5-58-53-Fc. The latter reagent showed moderately improved reactivity with HER-2/neu₃₆₉₋₃₇₇ peptide-pulsed T2 cells, when compared to scFv 2.3.5-58-53; however, it did not exhibit improved reactivity with HLA-A2⁺HER-2/neu⁺ tumor cells. We are actively investigating the reasons for the limited reactivity of our scFv-Fc reagent to these tumor cells.

In conclusion, the research activities supported by this DOD Predoctoral Fellowship Award have served as an ideal training vehicle for multiple laboratory techniques, including (i) the generation scFv-Fc fusion proteins via molecular biology approaches; (ii) the purification of scFv-Fc fusion proteins; and (iii) the analysis of the reactivity of scFv-Fc fusion proteins with HLA-A2:HER-2/neu peptide complexes, expressed either on peptide-pulsed T2 cells or HLA-A2⁺HER-2/neu⁺ tumor cells.

REFERENCE

1. Lo KM, Sudo Y, Chen J, Li Y, Lan Y, Kong SM, Chen L, An Q, Gillies SD. High level expression and secretion of Fc-X fusion proteins in mammalian cells. *Protein Eng* 1998; 11:495-500.